PATRYS LIMITED — Board/Management Information 2022

==> picture [135 x 44] intentionally omitted <==

ASX & Media Release

31 August 2022

Appointment of Non-Executive Director

Melbourne, Australia; 31 August 2022: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to announce the appointment of Mr Stefan Ross as a Non-Executive Director, effective today. Stefan is also Patrys’ Company Secretary.

Stefan has over 10 years of experience in accounting and secretarial services for ASX listed companies. His extensive experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting, shareholder meeting requirements, capital raising management, and board and secretarial support. Stefan has a Bachelor of Business majoring in Accounting.

Patrys is currently undertaking a search for a new Chair of the Board following the retirement of Mr John Read, which takes effect from the close of business on Wednesday, 31 August 2022, as announced on 8 August 2022. Mr Michael Stork will be interim Chair while the Company undertakes the search. It is intended that Mr Ross will step down from his position as a Director once a permanent Chair has been found.

-Ends-

This announcement is authorised for release by the Board of Directors of Patrys Limited.

For further information, please contact:

Registered Office Address

Level 4, 100 Albert Road South Melbourne VIC 3205

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at www.patrys.com.

1

==> picture [135 x 44] intentionally omitted <==

About Patrys’ deoxymab 3E10 platform:

Patrys’ deoxymab platform is based on the deoxymab 3E10 antibody. While most antibodies bind to cell surface markers, deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits the DNA repair processes. Cancer cells often have high levels of mutations and underlying deficiencies in the DNA repair mechanisms. For these reasons, the additional inhibition of the DNA repair processes by deoxymab 3E10 can kill cancer cells while having little impact on normal cells. As a single agent, deoxymab 3E10 has been shown to significantly enhance the efficacy of both chemoand radiotherapies in animal models of human cancer.

Patrys has developed two humanised forms of deoxymab 3E10, both which have improved activity over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In numerous pre-clinical studies, PAT-DX1 has shown significant ability to kill cancer cells in cell-based experimental systems, human tumour explants, xenograft and orthotopic models. PAT-DX1 has been shown to cross the blood-brain barrier, reduce tumour size, and increase survival in multiple animal models of brain cancer, non-brain cancers, and metastatic disease. PAT-DX1 is tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of pathology-specific tumour antigens. Patrys believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells. PAT-DX3, being a full-sized IgG molecule, also has potential for antibody drug conjugate (ADC) and antibody oligonucleoside conjugation (AOC) programs. A PAT-DX3 based ADC showed significant tumor targeting and survival benefit in proof-of-principle studies.

Patrys’ rights to deoxymab 3E10 are part of a worldwide license to develop and commercialise a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University as anti-cancer and diagnostic agents. Overall, nine patents in the portfolio have been granted with six patents covering the unconjugated form of deoxymab 3E10 (and derivatives thereof) granted (Europe, Japan, China, and 3 in the USA), and three patents covering nanoparticle conjugation (Australia, India and Canada).

2